Skip to main content

Advertisement

Table 1 Eligibility criteria

From: Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study

Inclusion criteria Exclusion criteria
Diagnosis of MCI due to AD or AD dementia based on patient history, neuropsychological assessment, and neuroimaging within the last 2 years Meeting the additional criteria of a non-AD neurodegenerative disease (vascular co-pathology is permitted)
Presence of NPS; ≥ 1 symptoms on NPI-Q Legally incapable to give informed consent
MMSE score > 15 Evidence of current delirium or previous delirium
Patients need to be community-dwelling Primary (premorbid) psychiatric disorders that could better explain the manifestation of NPS
Availability of a reliable informant Participating in a clinical (medication) trial
  1. MCI mild cognitive impairment, AD Alzheimer’s disease, NPS neuropsychiatric symptoms, NPI-Q Neuropsychiatric Inventory Questionnaire, MMSE Mini-Mental State Examination